These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 8787054)
21. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients. Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182 [TBL] [Abstract][Full Text] [Related]
24. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459 [TBL] [Abstract][Full Text] [Related]
25. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912 [TBL] [Abstract][Full Text] [Related]
26. CA 549 as a marker in breast cancer. Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307 [TBL] [Abstract][Full Text] [Related]
27. [Circulating proteinic biomarkers and breast cancer]. Mathelin C; Koehl C; Rio MC Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456 [TBL] [Abstract][Full Text] [Related]
28. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Steger GG; Mader R; Derfler K; Moser K; Dittrich C Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251 [TBL] [Abstract][Full Text] [Related]
29. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Nicolini A; Carpi A; Ferrari P; Pieri L Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486 [TBL] [Abstract][Full Text] [Related]
30. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816 [TBL] [Abstract][Full Text] [Related]
31. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients. Hu XC; Day W; Jones B; Loo WT; Chow LW Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883 [TBL] [Abstract][Full Text] [Related]
32. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480 [TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients. Jezersek B; Cervek J; Rudolf Z; Novaković S Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092 [TBL] [Abstract][Full Text] [Related]
34. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573 [TBL] [Abstract][Full Text] [Related]
35. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189 [TBL] [Abstract][Full Text] [Related]
36. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030 [TBL] [Abstract][Full Text] [Related]
37. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Stearns V; Yamauchi H; Hayes DF Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086 [TBL] [Abstract][Full Text] [Related]
38. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406 [TBL] [Abstract][Full Text] [Related]
39. Circulating CA 549 and other associated antigens in breast cancer patients. Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R Oncology; 1994; 51(1):18-21. PubMed ID: 8265097 [TBL] [Abstract][Full Text] [Related]
40. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer. Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]